Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.82 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 6/20 | 0.57 |
| ▸ | RARA | P10276 | 4/20 | 0.57 |
| ▸ | RARG | P13631 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.57 |
| ▸ | GOT1 | P17174 | 1/20 | 0.57 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405444 | 1.00 | HDAC11 (0.82) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL3291795 | 0.90 | HDAC11 (1.00) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL3291799 | 0.90 | HDAC11 (1.00) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL405796 | 0.90 | HDAC11 (0.80) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL405795 | 0.90 | HDAC11 (0.80) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL30015366 | 0.88 | HDAC11 (0.74) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL30015150 | 0.88 | HDAC11 (0.76) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL404024 | 0.88 | HDAC11 (0.76) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL404023 | 0.88 | HDAC11 (0.76) | HDAC11HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL15232880 | 0.86 | HDAC11 (0.64) | HDAC11HDAC2HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | claimed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | claimed |
| WO-2008077772-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-07-03 | — | — | WO | claimed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-8101793-B2 | Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease. | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| EP-1412317-B1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | SIGMA TAU IND FARMACEUTI (IT) | 2010-12-22 | — | — | EP | disclosed |
| EP-2101820-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2009-09-23 | — | — | EP | disclosed |
| US-7449495-B2 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-7449495-B2 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-11 | — | — | US | disclosed |
| WO-2008077772-A2 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-07-03 | — | — | WO | disclosed |
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-24 | — | — | US | disclosed |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-11-25 | — | — | US | disclosed |
| EP-1412317-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMOR AND PROAPOPTOTIC ACTIVITIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011808-A1 | RETINOID DERIVATIVES WITH ANTIANGIOGENIC, ANTITUMORAL AND PROAPOPTOTIC ACTIVITIES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021088-A1 | Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities | RARA, RARB, RXRA | HDAC11 741/4885HDAC2 2349/4885HDAC7 813/4885 |
| US-20040235757-A1 | Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities | RARA, RARB, RARG | HDAC11 883/4885HDAC2 2621/4885HDAC7 1007/4885 |
| US-20100330200-A1 | COMBINATION OF A RETINOID AND A PLATINUM ANTICANCER AGENT | CXCR4, RARA, CXCL12 | HDAC11 1919/4885HDAC2 3081/4885HDAC7 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.